APLM vs. PMN, MRKR, CASI, BCTX, JAN, DRRX, FBIO, IPA, SPRB, and VIRX
Should you be buying Apollomics stock or one of its competitors? The main competitors of Apollomics include ProMIS Neurosciences (PMN), Marker Therapeutics (MRKR), CASI Pharmaceuticals (CASI), BriaCell Therapeutics (BCTX), JanOne (JAN), DURECT (DRRX), Fortress Biotech (FBIO), ImmunoPrecise Antibodies (IPA), Spruce Biosciences (SPRB), and Viracta Therapeutics (VIRX). These companies are all part of the "pharmaceutical preparations" industry.
Apollomics (NASDAQ:APLM) and ProMIS Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.
Apollomics currently has a consensus price target of $2.00, suggesting a potential upside of 483.09%. ProMIS Neurosciences has a consensus price target of $8.00, suggesting a potential upside of 300.00%. Given Apollomics' higher possible upside, analysts plainly believe Apollomics is more favorable than ProMIS Neurosciences.
19.1% of Apollomics shares are held by institutional investors. Comparatively, 50.1% of ProMIS Neurosciences shares are held by institutional investors. 10.3% of ProMIS Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
ProMIS Neurosciences has lower revenue, but higher earnings than Apollomics.
In the previous week, Apollomics had 4 more articles in the media than ProMIS Neurosciences. MarketBeat recorded 7 mentions for Apollomics and 3 mentions for ProMIS Neurosciences. ProMIS Neurosciences' average media sentiment score of 0.96 beat Apollomics' score of 0.40 indicating that ProMIS Neurosciences is being referred to more favorably in the news media.
Apollomics has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. Comparatively, ProMIS Neurosciences has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.
Apollomics received 2 more outperform votes than ProMIS Neurosciences when rated by MarketBeat users. However, 100.00% of users gave ProMIS Neurosciences an outperform vote while only 80.00% of users gave Apollomics an outperform vote.
Summary
ProMIS Neurosciences beats Apollomics on 7 of the 13 factors compared between the two stocks.
Get Apollomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APLM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APLM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apollomics Competitors List
Related Companies and Tools
